Recipharm Enters into Collaboration with Vetcare
News Nov 19, 2012
Recipharm and Vetcare have announced the signing of an agreement for the development and manufacture of a parenteral veterinary product.
Specifically, the product concerned will be developed by Recipharm’s development site in Solna, Sweden and the commercial manufacturing is intended to take place at the company’s site in Monts, France.
Maria Lundberg, General Manager, Recipharm Pharmaceutical Development, commented: “We are pleased to have entered into this collaboration with Vetcare. This project is perfectly suited to Recipharm as it allows us to demonstrate our expertise in formulation and analytical method development with a challenging formulation before performing technology transfer to commercial manufacturing”.
“Michel Saudemon, General Manager of Recipharm in Monts added “this project is excellent news and is a perfect fit for our new smaller scale flexible manufacturing facility which will come on line next year”.
Kalevi Heinonen, Managing Director of Vetcare Oy, commented: “We view this as a highly important industry collaboration that will allow us to launch a novel product with the potential for significant improvement in animal health in the most efficient way. It was vital to us that we partnered with a company that could offer us both development and commercial manufacturing. Also the geographical locations, Sweden and France, are very suitable for us.
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018